A Highly Anticipated Selective Therapeutic Agent against CDK2: INX-315

In this issue, Dietrich, Trub, and colleagues describe and characterize a novel selective CDK2 inhibitor: INX-315. This agent shows promise in CCNE1-amplified cancers and in CDK4/6 inhibitor-resistant breast cancers. See related article by Dietrich et al., p. 446 (8).

Saved in:
Bibliographic Details
Published inCancer discovery Vol. 14; no. 3; pp. 386 - 388
Main Authors Watts, Lotte P, Spencer, Sabrina L
Format Journal Article
LanguageEnglish
Published United States 01.03.2024
Subjects
Breast Neoplasms - drug therapy
Breast Neoplasms - genetics
Cyclin-Dependent Kinase 2 - genetics
Cyclin-Dependent Kinase 4 - genetics
Female
Humans
Online AccessGet full text

Cover

More Information
Summary:In this issue, Dietrich, Trub, and colleagues describe and characterize a novel selective CDK2 inhibitor: INX-315. This agent shows promise in CCNE1-amplified cancers and in CDK4/6 inhibitor-resistant breast cancers. See related article by Dietrich et al., p. 446 (8).
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2159-8274
2159-8290
DOI:10.1158/2159-8290.CD-23-1537